Stocks:
5,782
ETFs:
2,400
Exchanges:
11
Market Cap:
$53.63T
24h Vol:
$9.51B
Dominance:
AAPL:5.58%
Stocklytics Platform
BETA
Instrument logo  HGEN

Humanigen, Inc.

HGEN
59 / 100
$0.00arrow_drop_down-23.07%-$0.00

Performance History

Placeholder
Key Stats
Open$0.00
Prev. Close$0.00
EPS-0.51
Dividend$0.00
Next Earnings DateMar 30, 2023
Dividend Yield %-
Market Cap$238.16K
PE Ratio-
LOWHIGH
Day Range0.00
0.00
52 Week Range0.00
0.24
Ratios
P/B Ratio9.20
Revenue$1.69M
Operating M. %-1,916.29%
Earnings-$53.63M
Earnings Growth %-
EBITDA Margin %-528.53%
ROE %-2,165.43%
EPS-0.51

Score Breakdown

59vs 53. Market Avg.

All Score (59 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

HGENMARKET
Value6640
Quality5945
Ownership139
Growth4445
Dividends-31

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$589.25
24H (%)arrow_drop_up0.18%
24H ($)$1.09
MARKET CAP$559.37B
PRICE$549.53
24H (%)arrow_drop_down-0.13%
24H ($)-$0.72
MARKET CAP$508.27B
PRICE$156.62
24H (%)arrow_drop_down-1.21%
24H ($)-$1.93
MARKET CAP$377.02B
PRICE$105.63
24H (%)arrow_drop_down-0.56%
24H ($)-$0.60
MARKET CAP$267.66B

About Humanigen, Inc. (HGEN)

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

ISN
-
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Cameron Durrant M.D., MBA
Headquarters
Short Hills
Employees
6
add Humanigen, Inc. to watchlist

Keep an eye on Humanigen, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.